Organization Profile

You just read:

Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C

News provided by

Bristol-Myers Squibb

Feb 25, 2014, 05:59 ET